BioEcho Life Sciences

BioEcho Life Sciences has developed a disruptive nucleic acid purification technology called EchoLUTION, which simplifies and accelerates the extraction process through a single-step, phenol- and chloroform-free method. The platform offers significant advantages in speed (up to 5x faster), cost (up to 57% lower), and scalability (up to 384-well format), making it attractive for high-throughput labs in academia, agriculture, and clinical research. With a focus on preserving sample integrity for downstream applications like qPCR and NGS, BioEcho is positioned as a challenger to established silica-membrane-based extraction kits from larger players.

EchoLUTION single-step nucleic acid purification technology. A gentle, phenol/chloroform-free method that allows nucleic acids to pass through a proprietary matrix while retaining contaminants, eliminating traditional bind-wash-elute steps.

BioEcho directly competes with the market-leading nucleic acid purification kits based on silica-membrane technology (e.g., Qiagen's RNeasy/QIAamp, Thermo Fisher's MagMAX, Promega's Wizard kits) and magnetic bead-based systems. Its differentiation is based on a simpler, faster, and gentler single-step process. It also competes with other alternative chemistry providers, but positions itself as a high-throughput, scalable solution for the research and potentially diagnostic markets.